CO2019007711A2 - N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga - Google Patents

N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga

Info

Publication number
CO2019007711A2
CO2019007711A2 CONC2019/0007711A CO2019007711A CO2019007711A2 CO 2019007711 A2 CO2019007711 A2 CO 2019007711A2 CO 2019007711 A CO2019007711 A CO 2019007711A CO 2019007711 A2 CO2019007711 A2 CO 2019007711A2
Authority
CO
Colombia
Prior art keywords
methyl
oxadiazol
thiazol
piperidyl
acetamide
Prior art date
Application number
CONC2019/0007711A
Other languages
English (en)
Inventor
Nicolas Jacques Francois Dreyfus
Peter James Lindsay-Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2019007711A2 publication Critical patent/CO2019007711A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención proporciona un compuesto de Fórmula I: o una sal farmacéuticamente aceptable del mismo, y el uso de compuestos de Fórmula I para el tratamiento de enfermedades y trastornos neurodegenerativos, tales como la enfermedad de Alzheimer.
CONC2019/0007711A 2017-01-27 2019-07-18 N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga CO2019007711A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451137P 2017-01-27 2017-01-27
PCT/US2018/014331 WO2018140299A1 (en) 2017-01-27 2018-01-19 N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Publications (1)

Publication Number Publication Date
CO2019007711A2 true CO2019007711A2 (es) 2019-07-31

Family

ID=61157343

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007711A CO2019007711A2 (es) 2017-01-27 2019-07-18 N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga

Country Status (37)

Country Link
US (1) US10081625B2 (es)
EP (1) EP3573983B1 (es)
JP (1) JP6738970B2 (es)
KR (1) KR102275338B1 (es)
CN (1) CN110198940B (es)
AR (1) AR110747A1 (es)
AU (1) AU2018213029B2 (es)
BR (1) BR112019013535A2 (es)
CA (1) CA3049141C (es)
CL (1) CL2019001978A1 (es)
CO (1) CO2019007711A2 (es)
CR (1) CR20190320A (es)
CY (1) CY1124257T1 (es)
DK (1) DK3573983T3 (es)
DO (1) DOP2019000187A (es)
EA (1) EA038368B1 (es)
EC (1) ECSP19053616A (es)
ES (1) ES2871949T3 (es)
HR (1) HRP20211011T1 (es)
HU (1) HUE054990T2 (es)
IL (1) IL267693B (es)
JO (1) JOP20190182B1 (es)
LT (1) LT3573983T (es)
MA (1) MA47368B1 (es)
MD (1) MD3573983T2 (es)
MX (1) MX2019008846A (es)
MY (1) MY197494A (es)
PE (1) PE20191406A1 (es)
PH (1) PH12019501707A1 (es)
PL (1) PL3573983T3 (es)
PT (1) PT3573983T (es)
RS (1) RS61979B1 (es)
SI (1) SI3573983T1 (es)
TW (1) TWI654978B (es)
UA (1) UA123472C2 (es)
WO (1) WO2018140299A1 (es)
ZA (1) ZA201904171B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030443A1 (en) 2014-08-28 2016-03-03 Asceneuron Sa Glycosidase inhibitors
KR20180132629A (ko) 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
ES2879351T3 (es) 2016-02-25 2021-11-22 Asceneuron Sa Sales de derivados de piperazina obtenidas por adición de ácidos
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
US20210323958A1 (en) * 2018-07-31 2021-10-21 Eli Lilly And Company 5-methyl-4-fluoro-thiazol-2-yl compounds
CA3107788A1 (en) * 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
SG11202102379XA (en) * 2018-09-19 2021-04-29 Biogen Ma Inc O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
TW202039482A (zh) 2018-12-05 2020-11-01 美商百健Ｍａ公司 嗎啉基、哌嗪基、氧氮雜環庚烷基及二氮雜環庚烷基o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃醣苷酶抑制劑
WO2020163193A1 (en) * 2019-02-04 2020-08-13 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
AU2020409728A1 (en) 2019-12-18 2022-08-11 Janssen Pharmaceutica Nv OGA inhibitor compounds
JP2023507180A (ja) 2019-12-18 2023-02-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｏｇａ阻害剤化合物
TW202220650A (zh) * 2020-07-23 2022-06-01 美商美國禮來大藥廠 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物
IL300365A (en) 2020-08-03 2023-04-01 Biogen Ma Inc Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitor
WO2023070064A1 (en) * 2021-10-22 2023-04-27 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
MX2008008337A (es) * 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
US20100063032A1 (en) * 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
DK2970272T3 (en) * 2013-03-14 2019-04-23 Merck Patent Gmbh glycosidase
US9732065B2 (en) * 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
WO2016030443A1 (en) * 2014-08-28 2016-03-03 Asceneuron Sa Glycosidase inhibitors
DK3389658T3 (da) 2015-12-18 2021-01-11 Merck Sharp & Dohme Glycosidasehæmmere og anvendelser deraf
CA3045957A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
EP3573983A1 (en) 2019-12-04
SI3573983T1 (sl) 2021-08-31
MY197494A (en) 2023-06-19
IL267693A (en) 2019-08-29
EA038368B1 (ru) 2021-08-17
US10081625B2 (en) 2018-09-25
PE20191406A1 (es) 2019-10-04
JP2020504142A (ja) 2020-02-06
JOP20190182A1 (ar) 2019-07-25
BR112019013535A2 (pt) 2020-01-07
CN110198940B (zh) 2022-09-23
CR20190320A (es) 2019-08-27
RS61979B1 (sr) 2021-07-30
MA47368B1 (fr) 2021-07-29
ES2871949T3 (es) 2021-11-02
EA201991515A1 (ru) 2020-01-16
AR110747A1 (es) 2019-05-02
PT3573983T (pt) 2021-06-17
CL2019001978A1 (es) 2019-12-13
MX2019008846A (es) 2019-09-10
CA3049141A1 (en) 2018-08-02
CA3049141C (en) 2021-02-16
EP3573983B1 (en) 2021-04-21
CY1124257T1 (el) 2022-07-22
DK3573983T3 (da) 2021-06-28
AU2018213029A1 (en) 2019-07-04
US20180215751A1 (en) 2018-08-02
KR20190096421A (ko) 2019-08-19
HRP20211011T1 (hr) 2021-09-17
DOP2019000187A (es) 2019-08-15
NZ754849A (en) 2021-10-29
PH12019501707A1 (en) 2020-03-16
LT3573983T (lt) 2021-07-26
UA123472C2 (uk) 2021-04-07
JP6738970B2 (ja) 2020-08-12
ECSP19053616A (es) 2019-08-30
JOP20190182B1 (ar) 2023-03-28
CN110198940A (zh) 2019-09-03
KR102275338B1 (ko) 2021-07-12
WO2018140299A1 (en) 2018-08-02
MD3573983T2 (ro) 2021-10-31
PL3573983T3 (pl) 2021-10-04
IL267693B (en) 2021-08-31
HUE054990T2 (hu) 2021-10-28
ZA201904171B (en) 2022-01-26
TWI654978B (zh) 2019-04-01
TW201836607A (zh) 2018-10-16
AU2018213029B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
AR103680A1 (es) Inhibidores selectivos de bace1
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
CO2020006224A2 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MY174747A (en) Bace1 inhibitors
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
EA201691160A1 (ru) Антагонисты s1p3
EA201692298A1 (ru) Производные карбоксамидов
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CR20170426A (es) Inhibidores de bace 1
EA201891447A1 (ru) Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
CO2020001375A2 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico
AR115865A2 (es) Compuestos terapéuticos